If you are a student, recent graduate or alumni interested in exploring a career in the biotechnology, pharmaceutical and life sciences industries, you are in the right place! Register today to start your job search and be contacted by employers nationwide looking for you! It only takes a few minutes and you will be on your way to the perfect job!
Monday, January 09, 2012
A webcast of Mr. Nielsen’s remarks will be available live. You can access the webcast at the Company’s website: http://www.biopathholdings.com .
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors, and its third candidate is a liposomal siRNA cancer drug that is in the final pre-clinical development stage. These product candidates and the delivery technology have been licensed from The University of Texas MD Anderson Cancer Center.
posted in: EmployerNews, News
Phoenix • Tucson • Palm Springs • Sacramento • San Diego • San Francisco • San Jose • Denver • Jacksonville • Miami • Orlando • Tampa • Atlanta • Chicago • Indianapolis • Kansas City • Louisville • New Orleans • Boston • Baltimore • Detroit • Grand Rapids • Minneapolis • Charlotte • Raleigh • Omaha • Atlantic City • Las Vegas • Reno • Buffalo • New York City • Cincinnati • Cleveland • Toledo • Tulsa • Portland • Philadelphia • Pittsburgh • Myrtle Beach • Memphis • Nashville • Austin • Dallas • Houston • San Antonio • Salt Lake City • Richmond • Seattle • Spokane
